OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.750
-0.030 (-1.69%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

OS Therapies Incorporated
OS Therapies logo
CountryUnited States
Founded2018
IPO DateAug 1, 2024
IndustryBiotechnology
SectorHealthcare
Employees5
CEOPaul Romness

Contact Details

Address:
115 Pullman Crossing Road, Suite 103
Grasonville, Maryland 21638
United States
Phone410-297-7793
Websiteostherapies.com

Stock Details

Ticker SymbolOSTX
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$4.00
CIK Code0001795091
ISIN NumberUS68764Y2072
Employer ID82-5118368
SIC Code2834

Key Executives

NamePosition
Paul A. Romness M.P.H.Founder, Chairman, President and Chief Executive Officer
Christopher P. AcevedoChief Financial Officer
Dr. Robert G. Petit Ph.D.Chief Medical Officer and Chief Scientific Officer
Jack DollChief of Staff
Gerald E. CommissiongChief Business Officer

Latest SEC Filings

DateTypeTitle
Jul 16, 2025DNotice of Exempt Offering of Securities
Jul 14, 20258-KCurrent Report
Jun 27, 20258-KCurrent Report
Jun 24, 20258-KCurrent Report
Jun 6, 2025EFFECTNotice of Effectiveness
May 28, 2025UPLOADFiling
May 23, 2025S-1General form for registration of securities under the Securities Act of 1933
May 16, 20258-KCurrent Report
May 15, 202510-QQuarterly Report
May 9, 2025SCHEDULE 13D/AFiling